Mgr. Michal Šmída, Dr. rer. nat.

2017

• LEDEREROVA, A; KOZLOVA, V; VAKULOVA, V; DOUBEK, M; MAYER, J; POSPISILOVA, S; SMIDA, M, 2017:B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE. HAEMATOLOGICA 102 , p. 709 - 709.

2016

• SMIDA, M; DE LA CRUZ, FF; KERZENDORFER, C; URAS, IZ; MAIR, B; MAZOUZI, A; SUCHANKOVA, T; KONOPKA, T; KATZ, AM; PAZ, K; NAGY-BOJARSZKY, K; MUELLNER, MK; BAGO-HORVATH, Z; HAURA, EB; LOIZOU, JI; NIJMAN, SMB, 2016:MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. NATURE COMMUNICATIONS 7
• SMIDA, M; KOZLOVA, V; VAKULOVA, V; LEDEREROVA, A; DOUBEK, M; MAYER, J; POSPISILOVA, S, 2016:Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy in B-Lymphoid Malignancies. BLOOD 128 (22)

2015

• DOUBEK, M; SMIDA, M, 2015:Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. EXPERT REVIEW OF HEMATOLOGY 8 (6), p. 743 - 764.
• ŠMÍDA, M, 2015:Chimérický antigenní receptor T lymfocytů- genová terapie budoucnosti u nádorových onemocnění?. KLINICKÁ ONKOLOGIE